Reported 19 days ago
Evan Seigerman from BMO Capital Markets discusses lucrative biotech investments outside the booming GLP-1 weight-loss drug market. He highlights companies like Regeneron and Vertex, emphasizing Vertex's advancements in cystic fibrosis treatments and partnerships with CRISPR Therapeutics for sickle cell disease therapies. Despite Vertex’s high stock price, the potential for innovative treatments remains strong, presenting an intriguing investment opportunity in the biotech landscape.
Source: YAHOO